Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
评价SI-B001单药或联合化疗治疗不可切除或转移性消化系统恶性肿瘤（结直肠癌、胃癌）的有效性、安全性和耐受性。
CTR20212617Phase 2Terminated
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of izalontamab in colorectal cancer (CRC), gastric cancer (GC), gastrointestinal neoplasia, sponsored by Biokin Pharmaceutical. Started Nov 2021; status: terminated.
02
Drugs
izalontamab
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)gastrointestinal neoplasia
Beyond the preview
Go deeper on CTR20212617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212617.